Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34
Innoviva, Inc.
Innoviva, Inc. INVA | 0.00 |
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:
INVA) with a Overweight and lowers the price target from $36 to $34.
